Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2005

View Archived Issues

MediBIC and Threshold sign glufosfamide codevelopment agreement

Dacogen NDA accepted for filing

SuperGen withdraws Orathecin NDA

AtheroGenics proposes amendments to ARISE trial of AGI-1067

NIK-333 set to enter phase II

Kinase inhibitors disclosed in Janssen patent

CRF receptor antagonists for depression, anxiety, etc.

Novel, selective estrogen receptor beta agonists in early development at Lilly

Celltech team describes novel series of chemokine CXCR3 receptor modulators

Pfizer claims compounds with dual 5-HT4 agonist/5-HT3 antagonist activity for GI disorders

New checkpoint kinase 2 inhibitors identified at Janssen

Amgen patent covers new cytokine inhibitors

New eNOS expression enhancers under investigation at Aventis

Characterization of the mechanism of action of the tumor-targeting combi-molecule ZR-2002

Pharmacokinetics of R-411 determined in healthy subjects

Afelimomab reduces mortality due to severe sepsis

Garenoxacin exposure-response relationship studied with trial data

FDA approves new oral solution formulation of Abilify

Ampligen investigated in HIV-1 patients coinfected with HCV

New data on the efficacy and safety of lapatinib in breast cancer

Enrollment under way in phase I study of TD-2749 for GI motility dysfunction

Preclinical and clinical studies evaluate the effects of interferon alpha on CNS

Olanzapine reported to reduce the risk of violent behavior in schizophrenia

VGV-1 reduces plasma viral load in HIV-infected patients not responding to antiretroviral therapy

Merck & Co. develops MB-243, a novel melanocortin receptor agonist

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...